GLPwatch
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
NCT00856609 · Completed
Last updated 2026-05-28This clinical trial tested whether the medication exenatide (Byetta) helps with weight loss by affecting energy use in adults who are obese but do not have diabetes.
What this study is testing ClinicalTrials.gov NCT00856609 ↗
Description as written by the study sponsor.
Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying. This randomized, placebo-controlled study is to evaluate whether exenatide over a 5 week period in non-diabetic obese subjects may lead to weight loss. To control for variability in individual response to weight loss treatment, this study will assess the role of exenatide in changing food intake and energy expenditure as possible sources of weight loss. This study will also evaluate the safety profile of exenatide in non-diabetic obese people. Additional assessments will evaluate changes in body fat and hormones involved in the sensations of hunger and fullness.
Treatments tested
- Byetta (exenatide) Drug
Exenatide is an injectable medication
- Weight loss Behavioral
Because response to weight loss
- Metabolic Chamber Other
The subject stays in the small room
- Placebo Drug
| Main thing measured | Energy Intake |
|---|---|
| Sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| Conditions studied | Weight Loss, Obesity |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00856609 ↗